title: Prognostic results of cisplatin IP and carboplatin IV with G-CSF in patients with ovarian cancer.
abstract: We performed a dose-escalation study of carboplatin combined with a fixed dose of intraperitoneal cisplatin and G-CSF in patients with epithelial ovarian cancer, and analyzed the progression-free and overall survival. Six of the patients who entered the study with stage IC and II disease are still alive with no evidence of disease. The five-year survival rate was 61% for the 18 patients with stage III and IV disease; progression-free survival over 5 years was 32%. Our results show this to be an effective treatment regimen for epithelial ovarian cancer. Prognosis is good with this combined carboplatin/cisplatin/G-CSF therapy, especially for those patients with microscopic or no residual disease.
authors: Department of Obstetrics and Gynecology, Hyogo College of Medicine, Hyogo 663, Japan. adachi@hyo-med.ac.jp
authors: S
authors: S
authors: Adachi
authors: Y
authors: Y
authors: Itani
authors: K
authors: K
authors: Ito
authors: T
authors: T
authors: Noda
authors: M
authors: M
authors: Shintani
authors: K
authors: K
authors: Saito
authors: N
authors: N
authors: Furukawa
authors: Y
authors: Y
authors: Tomii
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy / Q000473:pathology; D018262:Adenocarcinoma, Clear Cell / Q000188:drug therapy / Q000401:mortality / Q000473:pathology; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D016190:Carboplatin / Q000008:administration & dosage / Q000009:adverse effects; D018269:Carcinoma, Endometrioid / Q000188:drug therapy / Q000401:mortality / Q000473:pathology; D002675:Child, Preschool; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects; D018282:Cystadenocarcinoma, Mucinous / Q000188:drug therapy / Q000401:mortality / Q000473:pathology; D018284:Cystadenocarcinoma, Serous / Q000188:drug therapy / Q000401:mortality / Q000473:pathology; D018572:Disease-Free Survival; D004334:Drug Administration Schedule; D005260:Female; D005500:Follow-Up Studies; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use*; D006402:Hematologic Diseases / Q000139:chemically induced / Q000188:drug therapy / Q000517:prevention & control; D006801:Humans; D007262:Infusions, Intravenous; D007274:Injections, Intraperitoneal; D007564:Japan / Q000453:epidemiology; D015993:Life Tables; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D011379:Prognosis; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: D016179:Granulocyte Colony-Stimulating Factor; D016190:Carboplatin; D002945:Cisplatin